Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P J Neuvonen

Showing results (331-340 of 334) with videos related to

Pageof 34
Sort By:
You have reached the last page of results.This site can display upto 334 results.
International Journal of Clinical Pharmacology and Therapeutics|August 30, 2007
Effects of high-dose itraconazole treatment on lipoproteins in menB Schneider, R Gerdsen, J Plat, et al.
Acta Anaesthesiologica Scandinavica|May 1, 2007
Propofol versus alfentanil to prevent movement responses during uterine curettageE R J Seitsonen, E-S Cohen-Laroque, M J van Gils, et al.
Clinical Pharmacology and Therapeutics|June 28, 2014
Glucuronidation converts clopidogrel to a strong time-dependent inhibitor of CYP2C8: a phase II metabolite as a perpetrator of drug-drug interactionsA Tornio, A M Filppula, O Kailari, et al.
CPT: Pharmacometrics & Systems Pharmacology|July 10, 2013
A mechanistic, model-based approach to safety assessment in clinical developmentJ Lippert, M Brosch, O von Kampen, et al.
Pageof 34

Showing results (331-340 of 334) with videos related to

Sort By:
Pageof 34
You have reached the last page of results.This site can display upto 334 results.
International Journal of Clinical Pharmacology and Therapeutics|August 30, 2007
Effects of high-dose itraconazole treatment on lipoproteins in menB Schneider, R Gerdsen, J Plat, et al.
Acta Anaesthesiologica Scandinavica|May 1, 2007
Propofol versus alfentanil to prevent movement responses during uterine curettageE R J Seitsonen, E-S Cohen-Laroque, M J van Gils, et al.
Clinical Pharmacology and Therapeutics|June 28, 2014
Glucuronidation converts clopidogrel to a strong time-dependent inhibitor of CYP2C8: a phase II metabolite as a perpetrator of drug-drug interactionsA Tornio, A M Filppula, O Kailari, et al.
CPT: Pharmacometrics & Systems Pharmacology|July 10, 2013
A mechanistic, model-based approach to safety assessment in clinical developmentJ Lippert, M Brosch, O von Kampen, et al.
Pageof 34